Date: 2015-07-20
Type of information: Nomination
Compound:
Company: Atyr Pharma (USA - CA)
Therapeutic area: Rare diseases
Type agreement: nomination
Action mechanism:
Disease:
Details: * On July 20, 2015, aTyr Pharma, a biotherapeutics company engaged in the discovery and development of Physiocrine-based therapeutics to address severe rare diseases, announced that it will transition oversight of clinical development and operations to Kelly Blackburn and Melissa Ashlock, M.D., as David Weiner, M.D., transitions from his current position as aTyr\'s Chief Medical Officer into a clinical advisory role through the end of the first quarter of 2016. \"Our ongoing Phase 1b/2 clinical trial is continuing on track in facioscapulohumeral muscular dystrophy (FSHD) as the first orphan indication for Resolaris™, our natural immuno-modulator and lead product candidate, thanks to the leadership and expertise of David, Kelly and Melissa,\" said John Mendlein, Ph.D., CEO and executive chairman of aTyr Pharma. \"We want to thank David for his early contributions to our FSHD program, and we are pleased that he will remain with us as an advisor during this transition and our ongoing FSHD trial.\" Resolaris™, a first-in-class protein therapeutic, is currently being tested in an ongoing Phase 1b/2 clinical trial in adult patients with facioscapulohumeral muscular dystrophy (FSHD), and the Company also plans to initiate a Phase 1b/2 clinical trial in early onset FSHD patients in the third quarter of 2015. Additionally, aTyr expects to begin a Phase 1b/2 trial of Resolaris™ in LGMD (limb-girdle muscular dystrophy) 2B in the fourth quarter of 2015, as well as an additional trial in specific indications of interstitial lung disease, or ILD, in the first half of 2016.
Financial terms:
Latest news:
